Wellness News

Highlights from a presentation given by Robert Goldman, MD, PhD, FAASP, DO, FAOASM at the 2007 Anti-Aging London Conference entitled, New Science of Anti-Aging and Regenerative Medicine

At the upcoming Anti-Aging Conference: Clinical Applications for In-Office Procedures, will be giving the opening remarks on Friday morning, September 11th, 2009.

Dr. Robert M. Goldman has spearheaded the development of numerous international medical organizations and corporations. Robert Goldman. M.D., Ph.D., D.O., FAASP has served as a Senior Fellow at the Lincoln Filene Center, Tufts University, and as an Affiliate at the Philosophy of Education Research Center, Graduate School of Education, Harvard University. Dr. Goldman is a Clinical Consultant, Department of Obstetrics and Gynecology, Korea Medical University. He also serves as Professor, Department of Internal Medicine at the University of Central America Health Sciences (Belize). In addition, Goldman presently holds the position of Visiting Professor at Udayana Medical University (Indonesia). Dr. Goldman is a Fellow of the American Academy of Sports Physicians and a Board Diplomat in Sports Medicine and Board Certified in Anti-Aging Medicine.

Dr. Goldman received his Bachelor of Science Degree (B.S.) from Brooklyn College in New York, then conducted three years of independent research in steroid biochemistry and attended the State University of New York. He received the Doctor of Medicine (M.D.) Degree from the Central America Health Sciences University, School of Medicine in Belize, a government-sanctioned, Ministry of Health-approved, and World Health Organization-listed medical university. He received his Doctor of Osteopathic Medicine and Surgery (D.O.) degree from Chicago College of Osteopathic Medicine at MidWestern University. His Ph.D. work was in the field of androgenic anabolic steroid biochemistry.

He co-founded and serves as Chairman of the Board of Life Science Holdings, a biomedical research company with over 150 medical patents under development in the areas of brain resuscitation, trauma and emergency medicine, organ transplant and blood preservation technologies. He has overseen cooperative research agreement development programs in conjunction with such prominent institutions as the American National Red Cross, the US National Aeronautics and Space Administration (NASA), the Department of Defense, and the FDA’s Center for Devices & Radiological Health. Dr. Goldman is the recipient of the ‘Gold Medal for Science (1993), the Grand Prize for Medicine (1994), the Humanitarian Award (1995), and the Business Development Award (1996).

During the late l990s, Dr. Goldman received honors from Minister of Sports and government Health officials of numerous nations. In 2001, Excellency Juan Antonio Samaranch awarded Dr. Goldman the International Olympic Committee Tribute Diploma for contributions to the development of sport & Olympism. In addition, Dr. Goldman is a black belt in karate, Chinese weapons expert, and world champion athlete with over 20 world strength records, he has been listed in the Guinness Book of World Records. Some of his past performance records include 13,500 consecutive situps and 321 consecutive handstand pushups.

Dr. Goldman was an All-College athlete in four sports, a three time winner of the John F. Kennedy (JFK) Physical Fitness Award, was voted Athlete of the Year, was the recipient of the Champions Award, and was inducted into the World Hall of Fame of Physical Fitness. In 1995, Dr. Goldman was awarded the Healthy American Fitness Leader Award from the President’s Council on Physical Fitness & Sports and U.S. Chamber of Commerce. Dr. Goldman is Chairman of the International Medical Commission overseeing sports medicine committees in over 176 nations. He has served as a Special Advisor to the President’s Council on Physical Fitness & Sports. He is founder and international President Emeritis of the National Academy of Sports Medicine and the cofounder and Chairman of the American Academy of Anti-Aging Medicine (A4M). Dr. Goldman visits an average of 20 countries annually to promote brain research and sports medicine programs.

For more information, call; 1-888-997-0112.

Original post

A report in “The Federation of American Societies for Experimental Biology Journal” describes a new gene therapy vector which can transfer DNA to a cell’s nucleus far more efficiently than in the past. The development raises hopes for more effective treatment of genetic disorders and some types of cancers.

Gene therapy vectors deliver therapeutic DNA to a cell’s nucleus, where it reprograms a cell to function properly. “Effective gene therapy is clearly the best way to treat heritable diseases. It’s also an approach to other diseases where the environment or infection messes up our genes,” states Gerald Weissmann, M.D., Editor-in-Chief of “The FASEB Journal”.

The research conducted at the Nuclear Signaling Laboratory at Monash University in Victoria, Australia used proteins that mimic key functions of viruses for the packaging and transport of therapeutic DNA. “This work opens up a new era of pharmaceutical development,” according to Weissmann.

News source: http://www.eurekalert.org/pub_releases/2009-08/foas-ftz083109.php

Original post

Teams of doctors at Harvard Medical School, Cambridge University in England and elsewhere are studying the effect of Ateronon, a compound which provides the antioxidant properties of a Mediterranean diet. It is believed that Ateronon will provide a supplement formula free from side-effects.

Lycopene, the key ingredient in Ateronon, is a well-know antioxidant derived from tomatoes. Antioxidants block the breakdown of fats in the blood which leads to fat deposits on artery walls. By combining lycopene with a lactose-based milk protein, Ateronon has lycopene molecules small enough to be easily absorbed by humans.

A bio-technology spin-off company of Cambridge University, CTL, states that treatment with Ateronon can not only halt, but also reverse the build up of arterial fat in as little as eight weeks. “We are confident that Ateronon will show quite dramatic benefits in patients with heart and circulatory disorders…,” says Dr. Gunter Schmidt, the chief executive of CTL.

New source: http://www.telegraph.co.uk/health/healthnews/6114816/Mediterranean-diet-pill-to-help-prevent-heart-disease.html

Original post

Melanoma tumors with particular genetic mutations might respond to the drug lapatinib, already licensed for treating breast cancer tumors. Such a therapy would treat malignant melanoma in advanced stages with the common mutation called ERBB4 or HER4.

The study, conducted by the US National Human Genome Research Institute opens the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations. It also highlights a new approach to cancer research and treatment in which cancers are categorized according to the pattern of genetic mutations present.

Drugs that can target precise mutations could then be selected to personalize treatment to a tumor’s genetic characteristics. Tumors occuring in different parts of the body might sometimes be amenable to similar treatment strategies if they share similar genetic mutations, such as the breast and the skin.

News source: http://www.timesonline.co.uk/tol/news/science/medicine/article6815648.ece

Original post

Many people without any diagnosed risk for heart problems take low-dose aspirin in the hope that it will help prevent heart attacks and strokes. A trial lead by the Aspirin for Asymptomatic Atherosclerosis has found there is no preventive aspect in such routine use for healthy individuals.

“The findings of this study agree with our current advice that people who do not have symptomatic or diagnosed artery or heart disease should not take aspirin, because the risks of bleeding may outwiegh the benefits,” states Professor Peter Weissberg, of the British Heart Foundation which part-funded the latest research.

There is strong existing evidence which supports the use of low-dose aspirin to help prevent vascular problems in appropriate patients – those identified by their doctors to be at special risk due to factors such as familial history, stress and lifestyle.

News source: http://news.bbc.co.uk/2/hi/uk_news/8230048.stm

Original post

The drug methotrexate, first used in the 1940′s, has been found to destroy the damaged MSH2 gene prevelant in people with the genetic condition HNPCC. HNPCC contributes to bowel cancer, tumors of the stomach, womb, ovaries and kidneys.

MSH2 usually plays an essential role in repairing DNA damage. When the gene is damaged, mistakes in the genetic code of cells increase the risk of cancer. Methotrexate selectively destroys cells lacking the MSH2 function, providing a targeted therapy for patients with bowel cancer caused by MSH2 mutation.

The research, funded by Cancer Research UK, is welcomed by independent experts. Professor Will Steward of the charity Beating Bowel Cancer says, “This is good news from one of our oldest chemotherapy drugs. It won’t be for everyone, but it does hold out hope of a tailored treatment for those affected – a form of personalized chemotherapy.”

News source: http://news.bbc.co.uk/2/hi/health/8223441.stm

Original post

As technology advances in health, nutrition, and medicine, there is a race to figure out how to stop the effects of aging on the skin.  With all of the environmental pollutants we are exposed to on a daily basis, we need a way to protect our skin from these dangers.

This new Ageless Skin Care System is the first all-gel skin care that is designed to provide more nutritional protection for the skin than any other product on the market.  This video explains all:

For more information on this skin care line and the company that created it, visit Ageless WorldGel today!